FDA Urged to Consider Patients First
For Immediate Release
Milwaukee, WI (March 22, 2001) - Responding to comments by a consumer activist organization to end drug development of a treatment for irritable bowel syndrome (IBS), Nancy Norton, President and Founder of the International Foundation for Functional Gastrointestinal Disorders (IFFGD), today urged the FDA not to lose sight of the patients.
"The medical community has been slow in recognizing IBS as a legitimate disease. We are very concerned that 30 million Americans, mostly women, will be again forgotten by the medical system. IBS is a leading cause of absenteeism from work in the United States, costing the U.S. healthcare system over $8 billion a year.
"We urge the FDA to consider the patients first in making a decision on treatments for this devastating disease," says Norton.
For more information contact IFFGD at 414-964-1799.